On December 29, 2025, PTC Therapeutics, Inc. sold its remaining royalty rights on Roche’s Evrysdi product for $240 million upfront, plus potential future payments totaling $60 million based on sales metrics until 2029. As a result, PTC now owns 0% of the royalty, transferring full ownership to Royalty Pharma Investments.